Preparation method of bumetanib injection

By adding polyethylene glycol and mannitol to Bumetani injection and adopting specific preparation steps, the problem of drug release rate control is solved, achieving more effective therapeutic effects and product stability.

CN118986872APending Publication Date: 2024-11-22FUZHOU NEPTUNUS FUYAO PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411101186.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the drug release rate of Bumetani injection has not been effectively controlled, which has affected the therapeutic effect.

Method used

Add polyethylene glycol and mannitol to the injection and prepare it through specific stirring, filtration and sterilization steps to control the drug release rate and improve bioavailability.

Benefits of technology

It realizes the control of drug release rate, improves the bioavailability and therapeutic effect of drugs, and ensures the stability and safety of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004989420790000081
    Figure BDA0004989420790000081
  • Figure BDA0004989420790000082
    Figure BDA0004989420790000082
  • Figure BDA0004989420790000091
    Figure BDA0004989420790000091
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical preparations, in particular to a preparation method of bumetanib injection, which comprises the following steps: adding polyethylene glycol, osmotic pressure additive, bumetanib and sodium hydroxide into water for injection, stirring until liquid medicine is uniformly mixed, filtering, and finally encapsulating and sterilizing to obtain the bumetanib injection. Wherein the osmotic pressure additive is mannitol. The polyethylene glycol is added into the injection, and the high-molecular polymer can control the release rate of the medicine, so that potential toxicity and side effects are avoided, and a more stable treatment effect is achieved; meanwhile, the used water for injection is a 0.9% sodium chloride solution, and as a drug solvent, the sodium chloride solution contributes to improving the bioavailability of the drug in the body, also can supplement the sodium content of the human body and avoid sodium deficiency of the human body, so that the sodium chloride solution has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a method for preparing bumetanide injection. Background Art

[0002] Bumetanide injection is a derivative of m-aminobenzenesulfonamide and a potent diuretic. The role of diuretics in clinical practice cannot be underestimated. It can excrete excess water from the body in a short period of time and reduce cardiac preload. Therefore, diuretics are important routine medications. Diuretics inhibit the specific parts of the renal tubules from reacting with Na + , Cl - reabsorption, increase urine volume and Na + Excretion of excess water in the body, reducing Na + , water retention, reducing venous return, and lowering the preload of the heart. It is the only therapeutic drug that can fully control fluid retention in patients with heart failure.

[0003] In clinical practice, bumetanide injection is mainly used to treat liver disease, heart failure, kidney disease, etc. As a new type of loop diuretic, its mechanism of action is related to inhibiting the activity of Na-K-ATPase, mainly by inhibiting the thick ascending limb of the loop of Henle to Cl - Active reabsorption and Na + The passive reabsorption of urine affects the concentration and dilution process of urine and plays a diuretic role. In addition, unlike other diuretics, the glomerular filtration rate does not decrease while the renal tubular fluid flow increases with the loop diuretics, which may be related to the reduction of chloride flowing through the macula densa, thereby weakening or blocking the glomerular-tubular balance. During the treatment process, patients are not prone to diuretic resistance and basically no adverse reactions occur. As a powerful loop diuretic, bumetanide has the characteristics of rapid onset, rapid metabolism, wide administration routes, and few toxic and side effects. It is currently the most effective diuretic and is worthy of clinical promotion and application.

[0004] In the prior art, the release rate of the drug is not considered in the preparation of bumetanide injection. For example, patent CN116919893A discloses a bumetanide injection, which is composed of the following components: bumetanide, potassium chloride, furosemide, and water for injection, and provides a preparation process: bumetanide, potassium chloride, and furosemide are added to water for injection, and the bumetanide injection can be prepared after sufficient stirring. The bumetanide injection is mainly composed of bumetanide and supplemented with potassium chloride and furosemide, so that bumetanide and furosemide can jointly produce a diuretic effect; in the invention, it is pointed out that potassium chloride can supplement the potassium content of the human body and avoid injecting diuretics. After the dosage, the human body is deficient in potassium; Patent CN115487141A discloses a bumetanide injection, which is composed of the following components: active ingredient, osmotic pressure regulator, pH buffer, pH regulator. The invention uses xylitol as an osmotic pressure regulator, which has the effect of a stabilizer. Compared with the original preparation and other marketed preparations currently on the market, sodium chloride, disodium edetate and preservatives in the marketed products are removed, and the terminal sterilization process can be tolerated, reducing the aseptic risk in production and better improving the safety of the product. However, when producing bumetanide injection, it is necessary to consider controlling the release rate of the drug to provide a more stable therapeutic effect.

[0005] Therefore, according to the above-mentioned related technologies, it is urgent to develop a bumetanide injection that can control the drug release rate. Summary of the invention

[0006] In view of this, the object of the present invention is to provide a method for preparing bumetanide injection to solve the problem of drug release rate control of bumetanide injection in the prior art.

[0007] Based on the above objectives, the present invention provides a method for preparing bumetanide injection.

[0008] A method for preparing bumetanide injection comprises the following steps:

[0009] Step S1. Add polyethylene glycol and an osmotic pressure additive to water for injection in sequence, and stir until completely dissolved to obtain a mixed solution A;

[0010] Step S2. Add bumetanide to the mixed solution A, then add sodium hydroxide to adjust the pH of the system, and stir until completely dissolved; dilute to 1000 mL with water for injection, and stir until the liquid is evenly mixed to obtain a mixed solution B;

[0011] Step S3. Filtering the mixed solution B, collecting the filtrate, and obtaining a crude product of bumetanide injection;

[0012] Step S4. Filling and sterilizing the crude product of bumetanide injection to obtain bumetanide injection.

[0013] Preferably, the volume ratio of the water for injection, polyethylene glycol and osmotic pressure additive in step S1 is 800:50-60:48-55.

[0014] Preferably, the osmotic pressure additive in step S1 is mannitol, and the concentration of mannitol is 18%-25%.

[0015] Preferably, the water for injection in step S1 is a sodium chloride solution with a concentration of 0.9%.

[0016] Preferably, the polyethylene glycol in step S1 is PEG-400 with a concentration of 15%-30%.

[0017] Preferably, the mass ratio of bumetanide to sodium hydroxide in step S2 is 0.25-0.32:0.06-0.07.

[0018] Preferably, in step S2, the sodium hydroxide is used to adjust the pH of the system to 7.0-8.2.

[0019] Preferably, the filtration in step S3 uses microporous filtration with a pore size of 0.6-0.8 um.

[0020] Preferably, the microwave frequency during sterilization in step S4 is 500-700 MHz, and the sterilization time is 2-3 min.

[0021] Beneficial effects of the present invention:

[0022] The present invention provides a method for preparing bumetanide injection. In the present invention, polyethylene glycol is added to the injection, and the high molecular polymer can control the release rate of the drug; at the same time, the water for injection used is a 0.9% sodium chloride solution, which is used as a drug solvent to help improve the bioavailability of the drug in the body, and can also supplement the sodium content of the human body to avoid sodium deficiency in the human body after the diuretic is injected. Compared with the prior art, the bumetanide injection prepared by the present invention can control the release rate of the drug and improve the bioavailability of the drug, so it has a wide application prospect. DETAILED DESCRIPTION

[0023] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments.

[0024] The sources and properties of some of the raw materials used in the present invention are as follows:

[0025] Polyethylene glycol was purchased from Sinopharm Chemical Reagent Co., Ltd., model PEG-400; mannitol was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; sodium hydroxide was purchased from Jinan Huifengda Chemical Co., Ltd.; bumetanide was purchased from Guilin Nanyao Co., Ltd.; 0.9% sodium chloride water for injection was purchased from Shanghai Kanglang Biotechnology Co., Ltd.

[0026] Example 1: A method for preparing bumetanide injection, comprising the following steps:

[0027] Step S1. In 800 mL of 0.9% sodium chloride water for injection, 50 mL of 15% PEG-400 and 48 mL of 18% mannitol were added in sequence, and stirred until completely dissolved to obtain a mixed solution A;

[0028] Step S2. Add 0.25 g of bumetanide to the mixed solution A, and then add 0.06 g of sodium hydroxide to adjust the pH of the system to 7.0-8.2, and stir until completely dissolved; dilute to 1000 mL with water for injection, stir until the liquid is evenly mixed, and obtain a mixed solution B;

[0029] Step S3. Filtering the mixed solution B through a microporous filter with a pore size of 0.6 μm, collecting the filtrate, and obtaining a crude product of bumetanide injection;

[0030] Step S4. The crude product of bumetanide injection is sealed and sterilized at a microwave frequency of 500 MHz for 3 min to obtain bumetanide injection.

[0031] Example 2: A method for preparing bumetanide injection, comprising the following steps:

[0032] Step S1. In 800 mL of 0.9% sodium chloride water for injection, 54 mL of 20% PEG-400 and 50 mL of 20% mannitol were added in sequence, and stirred until completely dissolved to obtain a mixed solution A;

[0033] Step S2. Add 0.27 g of bumetanide to the mixed solution A, then add 0.064 g of sodium hydroxide and adjust the pH of the system to 7.0-8.2, and stir until completely dissolved; dilute to 1000 mL with water for injection, stir until the liquid is evenly mixed, and obtain a mixed solution B;

[0034] Step S3. Filtering the mixed solution B through a microporous filter with a pore size of 0.7 μm, collecting the filtrate, and obtaining a crude product of bumetanide injection;

[0035] Step S4. The crude product of bumetanide injection is sealed and sterilized at a microwave frequency of 550 MHz for 3 min to obtain bumetanide injection.

[0036] Example 3: A method for preparing bumetanide injection, comprising the following steps:

[0037] Step S1. In 800 mL of 0.9% sodium chloride water for injection, 57 mL of 25% PEG-400 and 53 mL of 22% mannitol were added in sequence, and stirred until completely dissolved to obtain a mixed solution A;

[0038] Step S2. Add 0.29 g of bumetanide to the mixed solution A, and then add 0.067 g of sodium hydroxide to adjust the pH of the system to 7.0-8.2, and stir until completely dissolved; dilute to 1000 mL with water for injection, and stir until the liquid is evenly mixed to obtain a mixed solution B;

[0039] Step S3. Filtering the mixed solution B through a microporous filter with a pore size of 0.75 μm, collecting the filtrate, and obtaining a crude product of bumetanide injection;

[0040] Step S4. The crude product of bumetanide injection is sealed and sterilized at a microwave frequency of 600 MHz for 2 min to obtain bumetanide injection.

[0041] Example 4: A method for preparing bumetanide injection, comprising the following steps:

[0042] Step S1. In 800 mL of 0.9% sodium chloride water for injection, 60 mL of 30% PEG-400 and 55 mL of 25% mannitol were added in sequence, and stirred until completely dissolved to obtain a mixed solution A;

[0043] Step S2. Add 0.32 g of bumetanide to the mixed solution A, and then add 0.07 g of sodium hydroxide to adjust the pH of the system to 7.0-8.2, and stir until completely dissolved; dilute to 1000 mL with water for injection, and stir until the liquid is evenly mixed to obtain a mixed solution B;

[0044] Step S3. Filtering the mixed solution B through a microporous filter with a pore size of 0.8 μm, collecting the filtrate, and obtaining a crude product of bumetanide injection;

[0045] Step S4. The crude product of bumetanide injection is sealed and sterilized at a microwave frequency of 700 MHz for 2 min to obtain bumetanide injection.

[0046] Comparative Example 1:

[0047] Compared with Example 1, PEG-400 was not added during the preparation of bumetanide injection in this comparative example, and the remaining steps and parameters were the same, which will not be repeated in this comparative example, and finally bumetanide injection was obtained.

[0048] Comparative Example 2:

[0049] Compared with Example 1, mannitol was not added during the preparation of bumetanide injection in this comparative example, and the remaining steps and parameters were the same, which will not be repeated in this comparative example, and bumetanide injection was finally obtained.

[0050] Comparative Example 3:

[0051] Compared with Example 1, this comparative example only replaces "mannitol with a concentration of 18%" with "mannitol with a concentration of 30%", and the remaining steps and parameters are the same, which will not be repeated in this comparative example, and finally bumetanide injection is obtained.

[0052] Comparative Example 4:

[0053] Compared with Example 1, this comparative example only replaces "PEG-400 with a concentration of 15%" with "PEG-400 with a concentration of 40%", and the remaining steps and parameters are the same, which will not be repeated in this comparative example, and finally bumetanide injection is obtained.

[0054] Performance Test:

[0055] Determination of the release rate of bumetanide injection:

[0056] 10 mL of the bumetanide injection prepared in Examples 1 to 4 and Comparative Examples 1 to 4 were added to dialysis bags of MD31 with a width of 31 mm and a diameter of 20 mm, respectively, and then the dialysis bags were placed in a container containing anhydrous ethanol and phosphate buffer, and maintained at 37° C., and a suitable stirring rate was maintained. Then, samples were taken at 5 min, 10 min, 20 min, 25 min, 30 min, 40 min, 1 h, and 2 h, and the drug concentration outside the dialysis bag was measured. The results are shown in Table 1;

[0057] Determination of the stability of Bumetanide injection:

[0058] The bumetanide injections prepared in Example 1 to Example 4 and Comparative Example 1 to Comparative Example 4 were packaged as intended for marketing and placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months. During the experiment, samples were taken at the end of the first month, second month, third month, and sixth month, and the appearance was compared. Various indicators were examined and the results were compared with those at 0 month. The results are shown in Tables 2 and 3.

[0059] Table 1 Summary of drug concentrations (mg / mL) of Examples 1-4 and Comparative Examples 1-4

[0060]

[0061] Table 2 Summary of accelerated experimental results of Example 1-Example 4 and Comparative Example 1-Comparative Example 4

[0062]

[0063]

[0064]

[0065] Table 3 Summary of bacterial endotoxin and sterility test results at the end of 6 months of accelerated experiments of Example 1-Example 4 and Comparative Example 1-Comparative Example 4

[0066] project Bacterial endotoxins Sterile Example 1 qualified qualified Example 2 qualified qualified Example 3 qualified qualified Example 4 qualified qualified Comparative Example 1 Failure Failure Comparative Example 2 Failure Failure Comparative Example 3 Failure Failure Comparative Example 4 Failure Failure

[0067] Data Analysis:

[0068] As can be seen from Table 1, the concentration of the bumetanide injection prepared by the present invention can reach a peak value in a relatively short time, because polyethylene glycol can be used to modify the surface of the drug carrier material to form a hydrophobic protective layer. This protective layer can reduce the direct contact between the drug and the external environment, reduce the initial burst release of the drug, and also prevent the drug from being rapidly metabolized or removed in the body, thereby achieving a sustained release effect. And mannitol, as an osmotic pressure additive, can cause the osmotic pressure in the blood to increase, prompting the water in the cells to move to the outside of the cells, thereby achieving a diuretic effect. Therefore, the bumetanide injection prepared by the present invention can exert its efficacy in a shorter time, better control the release rate of the drug, and achieve the desired therapeutic effect.

[0069] As for Comparative Example 1, since polyethylene glycol was not added, it can be seen from Table 1 that the time required for the concentration of bumetanide injection to reach the peak value was the longest and the drug effect was the slowest. This is because polyethylene glycol can better control the release rate of the drug. Therefore, the release rate shown in Comparative Example 1 is worse than that in Example 1. As for Comparative Example 2, since mannitol was not added, it can be seen from Table 1 that the time required for the concentration of bumetanide injection to reach the peak value was longer. This is because mannitol can increase the osmotic pressure in the blood, promote the movement of water in the cells to the outside of the cells, and have a diuretic effect. Therefore, the release rate shown in Comparative Example 2 is worse than that in Example 1. Comparative Example 3 adds "mannitol with a concentration of 18%" In Comparative Example 4, "PEG-400 at a concentration of 15%" is replaced with "PEG-400 at a concentration of 40%". It can be seen from Table 1 that the time required for the concentration of bumetanide injection to reach the peak value is longer. This is because the commonly used concentration of mannitol in clinical practice is about 20%, which has high effectiveness and safety. Therefore, the release rate shown in Comparative Example 3 is worse than that in Example 1. In Comparative Example 4, "PEG-400 at a concentration of 15%" is replaced with "PEG-400 at a concentration of 40%. It can be seen from Table 1 that the time required for the concentration of bumetanide injection to reach the peak value is longer. This is because the lower concentration of polyethylene glycol can increase the solubility of the drug. Therefore, the release rate shown in Comparative Example 4 is worse than that in Example 1.

[0070] As can be seen from Table 2, under the packaging conditions to be marketed, the bumetanide injection prepared in Examples 1 to 4 and Comparative Examples 1 to 4 were placed at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months. There was no significant change in the various indicators in Examples 1 to 4, but the properties of the bumetanide injection in Comparative Examples 1 to 4 changed from a colorless clear liquid to a small amount of turbid liquid, the pH value range was larger than that in Examples 1 to 4, and the clarity changed from qualified to unqualified; as can be seen from Table 3, at the end of the accelerated experiment for 6 months, the bacterial endotoxin and sterility tests in Examples 1 to 4 met the requirements, but the bacterial endotoxin and sterility tests in Comparative Examples 1 to 4 did not meet the requirements. This experiment shows that the bumetanide injection prepared by the present invention has good stability.

[0071] Those skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of the present invention is limited to these examples. Under the concept of the present invention, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of the different aspects of the present invention as described above, which are not provided in detail for the sake of simplicity.

[0072] The present invention is intended to cover all such substitutions, modifications and variations that fall within the broad scope of the appended claims. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for preparing bumetanide injection, It is characterized in that The preparation method of the bumetanide injection is as follows: Step S1. Add polyethylene glycol and an osmotic pressure additive to water for injection in sequence, and stir until completely dissolved to obtain a mixed solution A; Step S2. Add bumetanide to the mixed solution A, then add sodium hydroxide to adjust the pH of the system, and stir until completely dissolved; dilute to 1000 mL with water for injection, and stir until the liquid is evenly mixed to obtain a mixed solution B; Step S3. Filtering the mixed solution B, collecting the filtrate, and obtaining a crude product of bumetanide injection; Step S4. Filling and sterilizing the crude product of bumetanide injection to obtain bumetanide injection.

2. The method for preparing bumetanide injection according to claim 1, It is characterized in that The volume ratio of the water for injection, polyethylene glycol and osmotic pressure additive in step S1 is 800:50-60:48-55.

3. The method for preparing bumetanide injection according to claim 1, It is characterized in that In step S1, the osmotic pressure additive is mannitol, and the concentration of the mannitol is 18%-25%.

4. The method for preparing bumetanide injection according to claim 1, It is characterized in that The water for injection in step S1 is a sodium chloride solution with a concentration of 0.9%.

5. The method for preparing bumetanide injection according to claim 1, It is characterized in that The polyethylene glycol in step S1 is PEG-400 with a concentration of 15%-30%.

6. The method for preparing bumetanide injection according to claim 1, It is characterized in that The mass ratio of bumetanide to sodium hydroxide in step S2 is 0.25-0.32:0.06-0.

07.

7. The method for preparing bumetanide injection according to claim 1, It is characterized in that The sodium hydroxide in step S2 adjusts the pH of the system to 7.0-8.

2.

8. The method for preparing bumetanide injection according to claim 1, It is characterized in that The filtration in step S3 uses microporous filtration with a pore size of 0.6-0.8 um.

9. The method for preparing bumetanide injection according to claim 1, It is characterized in that The microwave frequency during sterilization in step S4 is 500-700 MHz, and the sterilization time is 2-3 minutes.